Table 2.
Changes in depressive symptoms throughout the study (pilot phase).
| Baseline | Week 2 | Week 4 | Week 6 | ||||
|---|---|---|---|---|---|---|---|
| Mean (SD) | Mean (SD) | % (SD) | Mean (SD) | % (SD) | Mean (SD) | % (SD) | |
| MADRS | 32.8 (2.68) | 26.8 (6.37) | 17.68 (21.16) | 21.4 (10.35) | 33.67 (32.99) | 22 (12.40) | 34.11 (35.97) |
| HDRS | 23.2 (2.86) | 19.8 (7.42) | 14.10 (32.42) | 15.8 (4.43) | 30.99 (21.82) | 16.8 (6.72) | 26.17 (30.10) |
| HAMA | 32 (6) | 24.6 (5.54) | 21.51 (20.14) | 20.4 (9.01) | 37.59 (19.00) | 22.8 (12.27) | 29.56 (30.03) |
| Response (%) | 0 | 2 (40) | 2 (40) | ||||
| Remission (%) | 0 | 0 (0) | 1 (20) | ||||
MADRS: Montgomery-Asberg Depression Rating Scale; HDRS: Hamilton Depression Rating Scale; HAMA: Hamilton Anxiety Rating Scale; YMRS: Young Mania Rating Scale; percentage represents percentage of change, calculated as ((score at time point − score at baseline)/score at baseline) ∗ 100. Clinical response was defined as >50% HDRS-17 score improvements from the baseline and the remission was defined as HDRS-17 score <8.